Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003882 · ClinicalTrials.gov registry record · Phase 1
Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00003882 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT00003882, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of anhydrovinblastine in treating patients who have advanced recurrent solid tumors.
Interventions
- DRUG anhydrovinblastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1999-03 |
| Est. Completion | 2000-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003882
The ClinicalTrials.gov registry entry for NCT00003882 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anhydrovinblastine is the first listed.
NCT00003882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003882 about?
NCT00003882 is a clinical study titled "Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of anhydrovinblastine in treating patients who have advanced recurrent solid tumors.
What is the current status of trial NCT00003882?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 1999-03. Estimated completion is 2000-09.
What interventions are being tested in trial NCT00003882?
The interventions under investigation include: anhydrovinblastine (DRUG).
Who is sponsoring clinical trial NCT00003882?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.